High Frequency Basal Cell Carcinoma (HF-BCC)

PellePharm to Highlight Clinical Programs at the 29th Congress of the European Academy of Dermatology and Venereology

Retrieved on: 
Thursday, October 29, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Syndromes, Clinical medicine, Organ systems, Gorlin, Nevoid basal-cell carcinoma syndrome, Patidegib, Gorlin Syndrome, High Frequency Basal Cell Carcinoma (HF-BCC), PellePharm, BridgeBio Pharma

The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 31, 2020.

Key Points: 
  • The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 31, 2020.
  • Our research continues to generate compelling evidence that supports patidegib as a clinical candidate and validates our approach in hedgehog inhibition.
  • Details for the poster presentations at EADV Virtual are as follows:
    We are encouraged by the continuing promise that patidegib is demonstrating in the clinic.
  • Patidegib topical gel has shown early promise in a Phase 2 clinical study for the mitigation of BCC tumors in Gorlin syndrome.

PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

Retrieved on: 
Monday, December 2, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Syndromes, Pharmacology, Nevoid basal-cell carcinoma syndrome, Gorlin, Topical medication, Hydrosal Gel, Patidegib, Gorlin Syndrome, High Frequency Basal Cell Carcinoma (HF-BCC), PellePharm, LEO Pharma, BridgeBio Pharma

PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in patients with Gorlin Syndrome.

Key Points: 
  • PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced the completion of enrollment for its pivotal Phase 3 clinical trial of Patidegib Topical Gel 2% vs. vehicle gel in patients with Gorlin Syndrome.
  • The randomized, double-blind, vehicle-controlled Phase 3 trial is evaluating the safety and efficacy of Patidegib Topical Gel 2% applied, twice daily to the face over 12 months vs. vehicle gel.
  • LEO Pharma is providing resources to PellePharm to fund, amongst other activities, its Phase 3 trial of Patidegib Topical Gel 2% in patients with Gorlin Syndrome under the terms of the agreement.
  • Patidegib Topical Gel has shown early promise in a Phase 2 clinical study for the mitigation of BCC tumors in Gorlin Syndrome.